奥锐特(605116) - 2025 Q2 - 季度财报

Section 1 Definitions Definitions of Common Terms This chapter defines common terms used in the report, including company and subsidiary names, pharmaceutical industry terms (e.g., API, GMP, FDA), and the reporting period, ensuring clarity and consistency - Aurisco/Company/Issuer refers to Aurisco Pharmaceutical Co., Ltd[12] - API refers to Active Pharmaceutical Ingredient, the main raw material used in the production of chemical preparations, and the active drug component in preparations[12] - FDA refers to the U.S. Food and Drug Administration, responsible for the management of drugs, food, biological products, cosmetics, veterinary drugs, medical devices, and diagnostic products across the United States[12] Section 2 Company Profile and Key Financial Indicators I. Company Information This section outlines Aurisco Pharmaceutical Co., Ltd.'s basic information, including its Chinese name, abbreviation, foreign name, and legal representative, providing essential identification details for investors - The company's Chinese name is Aurisco Pharmaceutical Co., Ltd., abbreviated as Aurisco, and its legal representative is Peng Zhien[15] II. Contact Person and Contact Information This section provides contact information for Board Secretary Li Fangfang and Securities Affairs Representative Wang Caibing, including address, phone, fax, and email, facilitating investor communication - The Board Secretary is Li Fangfang, and the Securities Affairs Representative is Wang Caibing; both can be contacted at Bado Industrial Park, Tiantai County, Zhejiang Province, with the email ir@aurisco.com[16] III. Brief Introduction to Changes in Basic Information This section states that the company's registered and office addresses have not changed, and provides the company's website and email, emphasizing no significant changes in basic information during the reporting period - The company's registered and office addresses are both located in Bado Industrial Park, Tiantai County, Zhejiang Province, with no changes during the reporting period[17] - The company's website is www.aurisco.com, and its email is ir@aurisco.com[17] IV. Brief Introduction to Changes in Information Disclosure and Document Custody Locations This section lists the company's designated newspapers and websites for information disclosure and states that there were no changes in information disclosure and document custody locations during the reporting period - The company's designated information disclosure newspapers include "Shanghai Securities News," "China Securities Journal," "Securities Times," and "Securities Daily," with the semi-annual report published on www.sse.com.cn[18](index=18&type=chunk) - There were no changes in the company's information disclosure and document custody locations during the reporting period[18] V. Company Stock Overview This section provides information on the company's A-share listing exchange, stock abbreviation, and stock code - The company's A-shares are listed on the Shanghai Stock Exchange, with stock abbreviation Aurisco and stock code 605116[19] VII. Company's Key Accounting Data and Financial Indicators During the reporting period, the company's key accounting data and financial indicators performed well, with significant growth in operating revenue and net profit, and improvements in earnings per share and return on net assets Key Accounting Data (Jan-Jun 2025 vs. Prior Year Period) | Key Accounting Data | Current Period (Jan-Jun) | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 821,967,093.05 RMB | 730,657,004.56 RMB | 12.50 | | Total Profit | 267,560,516.98 RMB | 216,371,569.90 RMB | 23.66 | | Net Profit Attributable to Shareholders | 234,897,927.99 RMB | 188,592,080.74 RMB | 24.55 | | Net Profit Attributable to Shareholders (Excl. Non-recurring) | 226,300,560.95 RMB | 187,113,195.53 RMB | 20.94 | | Net Cash Flow from Operating Activities | 215,360,022.22 RMB | 167,321,378.96 RMB | 28.71 | | Net Assets Attributable to Shareholders (Period-end) | 2,429,251,792.63 RMB | 2,331,528,721.53 RMB | 4.19 | | Total Assets (Period-end) | 3,902,507,684.21 RMB | 3,877,422,385.61 RMB | 0.65 | Key Financial Indicators (Jan-Jun 2025 vs. Prior Year Period) | Key Financial Indicators | Current Period (Jan-Jun) | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic EPS (RMB/share) | 0.58 | 0.46 | 26.09 | | Diluted EPS (RMB/share) | 0.58 | 0.46 | 26.09 | | Basic EPS (Excl. Non-recurring) (RMB/share) | 0.56 | 0.46 | 21.74 | | Weighted Average ROE (%) | 9.59 | 9.26 | increased by 0.33 percentage points | | Weighted Average ROE (Excl. Non-recurring) (%) | 9.24 | 9.19 | increased by 0.05 percentage points | [22] IX. Non-recurring Gains and Losses Items and Amounts This section details non-recurring gains and losses items and their amounts during the reporting period, totaling RMB 8,597,367.04, primarily including government subsidies and fair value changes in financial assets Non-recurring Gains and Losses Items and Amounts | Non-recurring Gains and Losses Item | Amount (RMB) | | :--- | :--- | | Disposal gains and losses of non-current assets | 73,768.62 | | Government grants recognized in profit or loss for the current period | 4,313,260.84 | | Gains and losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and gains and losses from disposal of financial assets and liabilities | 5,827,337.68 | | Other non-operating income and expenses | -106,951.52 | | Less: Income tax impact | 1,510,048.58 | | Total | 8,597,367.04 | [23][24] Section 3 Management Discussion and Analysis I. Description of the Company's Industry and Main Business Operations During the Reporting Period The company primarily engages in R&D, production, and sales of specialty APIs, pharmaceutical intermediates, and preparations, with no significant changes in its business model; the global pharmaceutical market continues to grow, while China's pharmaceutical industry, influenced by policies, is transitioning towards high-quality development, with the API sector benefiting from stricter environmental policies and volume-based procurement, leading to increased concentration and added value - The company primarily engages in the R&D, production, and sales of specialty complex APIs, pharmaceutical intermediates, and preparations, with operations across Europe, South America, North America, and Asia[28][29] - The company has obtained certifications from regulatory bodies such as NMPA, FDA, BGV, WHO, and ANVISA, becoming one of the domestic enterprises with a significant export volume of specialty APIs[29] - Global pharmaceutical expenditure is projected to reach approximately USD 2.2 trillion by 2028, with a CAGR of 6.6% from 2024-2028, driven by increased drug utilization, new product launches, patent expirations, and increased biosimilar use[37] - China's pharmaceutical manufacturing industry recorded operating revenue of RMB 2,529.85 billion in 2024, and total profit was RMB 342.07 billion, a 1.1% year-on-year decrease[39] - National policies guide the API industry towards high-quality development, with stricter environmental policies and institutionalized volume-based procurement driving increased industry concentration and added value[41][42] 1) Company's Main Business Operations During the Reporting Period%29%20Company's%20Main%20Business%20Operations%20During%20the%20Reporting%20Period) The company's core business involves the R&D, production, and sales of specialty complex APIs, pharmaceutical intermediates, and preparations, with products covering respiratory, cardiovascular,